Business Wire

CA-HAI-ROBOTICS

22.3.2022 11:44:04 CET | Business Wire | Press release

Share
HAI ROBOTICS to Debut Cutting-edge ACR Systems in U.S. at MODEX 2022

HAI ROBOTICS , the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will present its highly flexible totes-to-person warehouse automation solution at this year’s MODEX 2022 show, Booth C4585 at Georgia World Congress Center in Atlanta from March 28th to 31st.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005613/en/

With its robots being exhibited also by MHS, SVT Robotics, GreyOrange and Tompkins Robotics, the company will demonstrate alongside its strategic partners how its state-of-the-art warehousing technology complements the global supply chain.

Days ahead of MODEX 2022, HAI ROBOTICS announced new partnerships with Tompkins Robotics and Storage Solutions. The partnerships will see technology and solutions developed by HAI ROBOTICS being applied to various industries across North America.

Brian Reinhart, Vice President of Sales and Marketing at HAI ROBOTICS U.S., said the company would have a full display of its commitment to customers, partners and the U.S. market at the show after being in the market for over a year.

"It's a very exciting time for HAI ROBOTICS as we continue our expansion and growth in the U.S." he said. "In order to best serve the market and accommodate the requests of our end users, we are developing a robust, strong, and valuable partner network."

Reinhart, a veteran in the material-handling industry, says: "In a short time, we have planted deep roots in the U.S."

In addition to existing customers and partners, HAI ROBOTICS has established a U.S. HQ in Fremont, CA, a fully functional Demo Center with a decentralized sales and implementation strategy, positioning employees in 15 different states across the country.

The company's "ambitious goals have hiring, onboarding, and training of talented individuals as a top priority." "We want to be where our customers are to best serve them. We are committed to providing our partners with the best industry products, solutions, and service," he said.

Exhibits

The company's exhibits this year include two types of ACR robots and one workstation that were crafted to explore the full potentials of order-fulfillment efficiency, deployment flexibility and scalability in a goods-to-person order-handling context.

The HAIPICK A42T robot to be displayed is an evolution of the company’s IFOY 2021 "Best in Intralogistics" title earner. With a telescopic lift function that can flexibly adjust its picking height, it can handle bins (totes or cartons) at a storage height ranging from 0.28 to 10 meters.

It can carry 8 loads to feed goods-to-person workstations in one move, and shuttle between different storage areas without hindrance.

The HAIPICK A3 fork-lifting robot is a new invention that targets wider warehousing scenarios in addition to bin storage. It handles goods that don’t require a container, such as tires, trays and boards that can be lifted by a fork from the bottom. Its fork-lifting design brings an extra benefit of higher storage density, since spaces between neighboring bins can be reduced. This type of robot is a good match with working environments where control for dust, static and pollution is strict.

In addition to high flexibility, the HAIPICK robots outperform other goods-transporting robots by bringing every inch under the ceiling available for storage. However, it is the teamwork with the HAIPORT-powered Workstation that maximizes a warehouse’s throughput capacity.

A HAIPORT-powered Workstation , which can fulfill orders at in-bound and out-bound, involves collaboration between HAIPICK robots, HAIPORT and conveyor belts. HAIPORT is an automatic loading and unloading machine that can be docked with ACR robots and conveyor belts. At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the entry side of the HAIPORT, then transferred onto the conveyor belts for sorting per system orders and moved to the exit side of the HAIPORT, where they were fetched by robots for the next round of order processing.

The HAIPORT-powered Workstation is suitable for medium-to-large warehouses that have high throughput requirement of at least 400 bins per hour. It's machine rate can deliver 600 bins per hour to an operator. It suits for extensive storage scenarios in which medium and small-sized bins are used, such as raw materials, small electronics, apparel, medicine, retails and 3PL industries that have large number of SKUs.

ABOUT HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye